baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

SPEXIS N/ CH0106213793 /

5/31/2024 5:30:41 PM	Chg. -	Volume	Bid2:04:54 PM	Ask2:04:54 PM	Market Capitalization	Dividend Y.	P/E Ratio
0.0618CHF	-	620,217 Turnover: 37,326.5938	0.0570Bid Size: 10,000	-Ask Size: 1,500	3.01 mill.CHF	-	-

GlobeNewswire 4/25 Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of ...

GlobeNewswire 4/9 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

GlobeNewswire 2/13 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...

GlobeNewswire 1/15 Basilea announces acquisition of preclinical antibiotics program from Spexis

GlobeNewswire 11/1/2023 Spexis Announces Changes to the Executive Committee

GlobeNewswire 10/6/2023 Spexis to host business update conference call on October 9, 2023

GlobeNewswire 9/29/2023 Spexis provides business update and announces financial results for the first half of 2023

GlobeNewswire 9/28/2023 Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

GlobeNewswire 8/15/2023 Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studie...

GlobeNewswire 6/28/2021 Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced ...

GlobeNewswire 6/8/2021 Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe ...

GlobeNewswire 6/1/2021 Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activi...

GlobeNewswire 5/18/2021 Polyphor to Present at the UBS Global Healthcare Virtual Conference

GlobeNewswire 3/5/2021 Polyphor Announces Financial Results for the Full-Year 2020

GlobeNewswire 2/26/2021 Polyphor to Present Full-Year 2020 Financial Results on March 5

GlobeNewswire 1/5/2021 Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Ann...

GlobeNewswire 12/22/2020 Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

GlobeNewswire 12/14/2020 Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to Continue Pha...

GlobeNewswire 12/11/2020 Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of ...

GlobeNewswire 11/24/2020 Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinica...

GlobeNewswire 10/29/2020 Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer

GlobeNewswire 10/14/2020 Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic p...

GlobeNewswire 9/29/2020 Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receip...

SPEXIS N/ CH0106213793 /

If you wish to receive reply to your feedback, please provide your email address.